EUVIMEDOpdag EUVIMED
Crossref

Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors

Franck Carbonnel iD, Emilie Routier, Thierry Lazure, Charlotte Mussini, Christophe Bellanger, Carine Merklen, Bakhtiar Bejou, Anthony Buisson iD, Aurélien Amiot iD, Antoine Meyer iD, Catherine Dong iD, Caroline Robert

Alimentary Pharmacology & Therapeutics · 2023-04 · 57 (7) · 792-799

DOI: 10.1111/apt.17352 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2022-12-28. Written by Franck Carbonnel and 11 co-authors. Institution: Service de Gastroentérologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France. Major MEDLINE topics: Melanoma, Skin Neoplasms. Cited 10 times so far (Crossref); 15 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Dual blockade of BRAF and MEK kinases is a standard of care for metastatic V600E/K BRAF mutant melanoma. This study reports the first systematic description of colitis due to BRAF and MEK inhibitors.

Methods

We studied consecutive patients with melanoma, treated with BRAF and MEK inhibitors, who had colitis requiring hospitalisation. Electronic files were studied; endoscopic biopsies and colectomy specimens were read centrally.

Results

Between January 2021 and March 2022, nine women and one man, aged 50–90 years, were studied. Nine patients received encorafenib and binimetinib; one patient received dabrafenib and trametinib. The main symptoms were diarrhoea, haematochezia, abdominal pain and intestinal obstruction. Blood tests showed anaemia, increased CRP and low serum albumin levels in most patients. All patients had ulcerations of the right colon with (2/10) or without (8/10) stenosis of the ileocecal valve, and 4/10 patients also had ulcerations distal to the right colon. Histopathological findings were suggestive of ischaemia and mild inflammation. Nine of the 10 patients discontinued BRAF/MEK inhibitors. Drugs were reintroduced in four patients, three of whom had a severe relapse of diarrhoea. Two patients required surgery and underwent intestinal resection. One patient died of enterocolitis.

Conclusion

BRAF/MEK inhibitors can induce severe colitis characterised by ulcerations of the right colon.

Subjects

MeSH terms (MEDLINE)

MelanomaSkin NeoplasmsFemaleHumansMaleAntineoplastic Combined Chemotherapy ProtocolsMitogen-Activated Protein Kinase KinasesMutationNeoplasm Recurrence, LocalProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Author keywords

BRAF/MEK inhibitorcolitismelanoma

Substances

BRAF protein, humanMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Authors and institutions

  • Service de Gastroentérologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
  • Université Paris Saclay, Le Kremlin Bicêtre, France.
  • Centre de Recherche en Épidémiologie et Santé des Populations (CESP, Inserm U1018), Villejuif, France.
  • Dermatology Unit, Department of Medicine, Institute Gustave Roussy, Villejuif, France.
  • Laboratoire d'Anatomopathologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
  • Service de Dermatologie, Hôpitaux Civils de Colmar, Colmar, France.

ORCID profiles: Franck Carbonnel, Anthony Buisson, Aurélien Amiot, Antoine Meyer, Catherine Dong

Cite

APA

Carbonnel, F., Routier, E., Lazure, T., Mussini, C., Bellanger, C., Merklen, C., Bejou, B., Buisson, A., Amiot, A., Meyer, A., Dong, C., & Robert, C. (2023). Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors. Alimentary Pharmacology & Therapeutics, 57(7), 792-799. https://doi.org/10.1111/apt.17352

Vancouver

Carbonnel F, Routier E, Lazure T, Mussini C, Bellanger C, Merklen C, et al. Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors. Alimentary Pharmacology & Therapeutics. 2023;57(7):792-799. doi:10.1111/apt.17352

BibTeX
@article{Carbonnel2023,
  author = {Carbonnel, Franck and Routier, Emilie and Lazure, Thierry and Mussini, Charlotte and Bellanger, Christophe and Merklen, Carine and Bejou, Bakhtiar and Buisson, Anthony and Amiot, Aurélien and Meyer, Antoine and Dong, Catherine and Robert, Caroline},
  title = {Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {7},
  pages = {792--799},
  doi = {10.1111/apt.17352}
}
Start for free →